CMS Proposal To Expand Aprepitant Coverage Could Also Benefit Tesaro’s Rolapitant
This article was originally published in The Pink Sheet Daily
CMS’ proposed update to its Medicare Part B National Coverage Determination would provide payment for aprepitant when used for patients receiving moderately emetogenic chemotherapy, not just highly emetogenic treatments.
You may also be interested in...
Tesaro’s three-drug oncology program, including its lead NK-1 product for chemo-induced nausea and vomiting, is boosted by a recent raise from the public markets.
CMS includes genetic testing on its updated list of potential topics for Medicare national coverage determinations, released Nov. 27. But no biopharmaceuticals are on the list this time around.
The current Medicare Part B national coverage determination says use of the anti-nausea drug with highly emetogenic anti-cancer chemotherapy is reasonable and necessary; the National Comprehensive Cancer Network asks CMS to update the NCD based on evidence supporting use with moderately emetogenic agents.